UPDATED: Amgen scraps or halts a slate of 5 cancer studies in a series of setbacks. But execs focus on mastering 'induced proximity'
Amgen rolled out their Q4 numbers Tuesday afternoon, while flagging that a long lineup of its cancer therapy studies has been halted as they review safety questions on one drug and scrap several others in a pipeline reorganization. But the main R&D focus during the call with analysts revolved around plans to make Amgen the industry leader in what execs are calling “induced proximity.” And they sound prepared to ink some BD deals to make that happen.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,700+ biopharma pros reading Endpoints daily — and it's free.